Elicio Therapeutics set its 2026 annual stockholder meeting for November 12 and established September 24 as the deadline for proposals, director nominations and certain proxy notices. The dates give investors a defined timetable for submitting matters for consideration and seeking inclusion in the company’s proxy materials.
Key Highlights
- Elicio Therapeutics set its 2026 annual meeting for November 12, 2026.
- Stockholder proposals under Rule 14a-8 must be received by September 24, 2026.
- Bylaw notices for director nominations and other matters, along with required Rule 14a-19 notices, must be provided by September 24, 2026.
Elicio Therapeutics, Inc. (NASDAQ: ELTX) has set November 12, 2026, for its annual meeting of stockholders. The company will provide the meeting’s exact time, location and voting matters in its proxy statement.
September 24 Deadline Covers Proposals and Nominations
Stockholder proposals intended for inclusion in the proxy materials must reach Elicio Therapeutics by September 24, 2026. Proposals must comply with the company’s amended bylaws and applicable Securities and Exchange Commission requirements. Director nominations and other matters submitted under the bylaws must also arrive by September 24, 2026, for consideration at the annual meeting.
FAQs
Q: When is Elicio Therapeutics’ 2026 annual meeting?
A: Elicio Therapeutics’ 2026 annual meeting of stockholders is scheduled for November 12, 2026. The proxy statement will provide the exact time, location and voting matters.
Q: What is the deadline for ELTX stockholder proposals?
A: September 24, 2026, is the deadline for stockholder proposals intended for inclusion in Elicio Therapeutics’ proxy materials. Proposals must meet applicable requirements.
Q: When must Elicio Therapeutics director nominations be submitted?
A: Director nominations and other matters submitted under Elicio Therapeutics’ bylaws must reach the company secretary by September 24, 2026, for consideration at the annual meeting.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.